Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
Anti-drug antibodies (ADA) can limit the efficacy and safety of therapeutic antibodies. However, determining the exact nature of ADA interactions with the target drug via epitope mapping is challenging due to the polyclonal nature of the IgG response. Here, we demonstrate successful proof-of-concept...
Main Authors: | Arthur J. Schick, Victor Lundin, Justin Low, Kun Peng, Richard Vandlen, Aaron T. Wecksler |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/19420862.2022.2028337 |
Similar Items
-
Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods
by: Corie Y. Ralston, et al.
Published: (2022-11-01) -
Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01) -
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
by: Sivan Cohen, et al.
Published: (2021-01-01) -
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies
by: Xibei Dang, et al.
Published: (2023-12-01) -
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
by: Elizabeth Sara Hecht, et al.
Published: (2022-12-01)